Back to search

Switzerland· 16951001

Novalgin, Oblong-Tabletten

A metamizole sodium product, registered in Switzerland by Opella Healthcare Switzerland AG and dispensed under Swissmedic category B. The same ATC class is registered in 8 of our 19 countries.

Cat B (Swissmedic)ATC N02BB02

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedNovalgin, Oblong-TablettenATCN02BB02REGISTER NO.16951001PACKS LISTED0CHECKEDJune 26, 2026

Where it is registered

Metamizole sodium is registered in 8 of 19 countries.

Countries holding a registration under ATC N02BB02 (metamizole sodium), each read from that country’s own register.

  • This record: Switzerland
  • 6 of them publish a price we can compare per daily dose

Metamizole sodium · ATC N02BB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of metamizole sodium costs, country by country.

Normalised to the WHO defined daily dose (3 g), so markets compare like for like.

  • Switzerland: $3.00 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Metamizole sodium · price per daily dose (3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.00
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Manufacturer
Opella Healthcare Switzerland AG
Country
Switzerland (CH)
ATC code
N02BB02
ATC class
Metamizole sodium
Defined daily dose
3 g, O
Swissmedic category
B
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for metamizole sodium.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Metamizole sodium · interactions on record

5 records

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d99d7554-6e8c-4ab6-bce0-79dcb419e0a2
GET /v1/drugs/d99d7554-6e8c-4ab6-bce0-79dcb419e0a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}

See everything about metamizole sodium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.